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Integration of Smad and Forkhead Pathways
in the Control of Neuroepithelial and
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Jennings and Pietenpol, 1998; Siegel and Massague´,
2003). The TGF- cytostatic program involves tran-
scriptional activation of the cyclin-dependent kinase in-
hibitors p21Cip1 and p15Ink4b and repression of the
growth-promoting transcription factors c-myc and Id1-
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Smad complexes mediating p21Cip1 and p15Ink4b acti-
vation. c-Myc levels must be below a certain threshold
in order for p21Cip1 and p15Ink4b to be activated bySummary
TGF- and other cytostatic signals. When present at
high levels, as in mitogen-stimulated cells, c-Myc bindsFoxO Forkhead transcription factors are shown here
to the p21Cip1 and p15Ink4b promoters via the zincto act as signal transducers at the confluence of Smad,
finger protein Miz-1, interfering with activation of thesePI3K, and FoxG1 pathways. Smad proteins activated
genes by TGF- (Seoane et al., 2002, 2001; Staller etby TGF- form a complex with FoxO proteins to turn
al., 2001), the tumor suppressor p53 (Seoane et al.,on the growth inhibitory gene p21Cip1. This process
2002), and other signals (Herold et al., 2002; van deis negatively controlled by the PI3K pathway, a known
Wetering et al., 2002; Wu et al., 2003). c-Myc downregu-inhibitor of FoxO localization in the nucleus, and by
lation by TGF- renders p21Cip1 and p15Ink4b compe-the telencephalic development factor FoxG1, which
tent for activation. However, relief from c-Myc repres-we show binds to FoxO-Smad complexes and blocks
sion is not sufficient for activation (Seoane et al., 2002,p21Cip1 expression. We suggest that the activity of this
2001). It has been proposed that activation of p21Cip1network confers resistance to TGF--mediated cyto-
and p15Ink4b by TGF- additionally requires the input ofstasis during the development of the telencephalic
a transactivation complex (Feng et al., 2000; Moustakasneuroepithelium and in glioblastoma brain tumor cells.
and Kardassis, 1998; Seoane et al., 2001).
Here, we identify FoxO proteins as key partners of
Introduction Smad3 and Smad4 in the TGF--dependent generation
of a p21Cip1 activation complex. FoxO factors are mem-
TGF- is a pleiotropic cytokine that delivers cytostatic bers of the Forkhead box (Fox) family, which figures
signals to epithelial, neuronal, and immune cells (Siegel prominently in the control of cell and organismal growth,
and Massague´, 2003; Wakefield and Roberts, 2002). development, metabolism, and longevity (Lee et al.,
TGF- activates a membrane receptor serine/threonine 2003; Libina et al., 2003; Murphy et al., 2003; Tran et al.,
kinase complex that phosphorylates Smad2 and Smad3 2003; Czech, 2003). FoxO factors are under negative
(Shi and Massague´, 2003). Once activated, Smads accu- control by the PI3K (phosphatidyl insositol 3-kinase)
mulate in the nucleus and form transcriptional com- growth-promoting pathway (Tran et al., 2003; Czech,
plexes with Smad4 and different DNA binding partners, 2003; Vivanco and Sawyers, 2002). In response to mito-
coactivators, and corepressors. These complexes tar- genic signals, PI3K activates Akt (or PKB), a protein
get different genes, depending on their composition kinase that phosphorylates FoxO proteins, barring them
(Derynck et al., 1998; Massague´ and Wotton, 2000; Miya- from the nucleus and thus from target genes (Brunet et
zawa et al., 2002), and collectively generate hundreds al., 1999). The present identification of FoxO factors
of immediate gene responses (Kang et al., 2003; Yang as Smad partners in p21Cip1 activation provides a link
et al., 2003). Identifying these Smad partners, therefore, between the TGF-/Smad and PI3K/Akt pathways and
is essential for delineating cell-specific programs of suggests a broader role for FoxO proteins as signal
TGF- action and their integration in signaling networks. transducers.
The TGF- cytostatic response is of interest, because Our analysis further reveals that FoxO-Smad com-
its loss contributes to tumor development (Dumont and plexes are also inhibited by FoxG1, a distinct Forkhead
Arteaga, 2003; Siegel and Massague´, 2003; Wakefield family member that is essential for neuroepithelial devel-
and Roberts, 2002). Carcinoma and glioblastoma cells opment during telencephalon formation in the mouse
(Xuan et al., 1995) and suppresses early cortical cell fatethat avert TGF--mediated cytostasis may use this fac-
(Hanashima et al., 2004, 2002). Further, the combinedtor with impunity to exacerbate their own proliferative,
actions of FoxG1 and PI3K mediate the intrinsic resis-invasive, and metastatic behavior (Derynck et al., 2001;
tance of human glioblastoma cells to TGF- induction of
p21Cip1 and growth inhibition. Thus, three pathways—the*Correspondence: j-massague@ski.mskcc.org
Smad, PI3K, and FoxG1 pathways—converge on FoxO3Present address: Medical Oncology Program, Vall d’Hebron Univer-
factors to influence epithelial and neuronal growthsity Hospital Research Institute, ICREA, Passeig Vall d’Hebron 119-
129, 08035 Barcelona, Spain. and oncogenesis.
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Figure 1. Inputs into the p21Cip1 Promoter
(A) Schematic representation of the p21Cip1 promoter and the dual TGF- input. The nucleotide sequence of the human and mouse p21Cip1
Smad binding region (SBR) are indicated. The Forkhead binding element (FHBE, green), Smad binding elements 1–4 (SBE, orange), Myc-Miz1
binding element (gray), and mutations targeting these sites are indicated.
(B) HaCaT cells were treated with 100 pM TGF- or no additions for 1 hr and subjected to ChIP assays with the indicated antibodies and
PCR primers. -actin served as a TGF- unresponsive control.
(C) HaCaT cells were incubated with or without TGF- for 1 hr, and cell lysates were precipitated with the indicated wild-type (WT) or mutant
(mSBE1,2) biotinylated double-stranded p21Cip1 SBR oligonucleotides probes. The presence of Smad4 in the precipitates was determined
by immunoblotting.
(D) HaCaT cells transfected with promoter constructs driving luciferase were incubated with or without TGF- for 20 hr, and luciferase activity
was determined.
(E) HaCaT-tetMyc cells transfected with promoter constructs were withdrawn from tetracycline for 20 hr in order to induce c-Myc expression
(ON) or left with tetracycline (OFF). TGF- was added for 20 hr, and luciferase activity was determined.
(F) HaCaT-tetMyc cells were cultured in the presence or absence of tetracycline for 20 hr and then with or without TGF- for 4 hr. Cell lysates
were incubated with a biotinylated double-stranded p21Cip1 SBR oligonucleotide probe. The precipitated complexes were subjected to anti-
Smad4 immunoblot analysis and the total cell lysates to anti-Myc immunoblot analysis.
Results we identified a Smad binding region (SBR) that contains
four Smad binding elements (SBE, 5-AGAC-3 [Zawel
et al., 1998]) (Figure 1A). As a synthetic oligonucleotide,A Smad Input Controlling p21Cip1
In mitogen-stimulated epithelial cells, a c-Myc-Miz com- this region binds to an endogenous TGF--dependent
Smad complex (Figure 1C), and in front of a reporterplex binds to the proximal region in the p21Cip1 pro-
moter and inhibits transcription (Herold et al., 2002; gene, it mediates TGF--dependent transactivation (Fig-
ure 1D). Both activities require the integrity of the SBEs,Seoane et al., 2002; van de Wetering et al., 2002) (sum-
marized in Figure 1A). On TGF- addition, Smad3 and as determined using SBE mutant versions (Figures 1C
and 1D).Smad4 form a complex with E2F4/5 and p107 to repress
c-myc (Chen et al., 2002). The ensuing drop in c-Myc Although c-Myc inhibited the TGF- response of the
p21Cip1 promoter, it had no effect on the response oflevels relieves p21Cip1 from inhibition, enabling its trans-
activation by a hypothetical TGF--dependent Smad the isolated SBR (Figure 1E) and did not diminish Smad
binding to the SBR (Figure 1F). Collectively, these resultscomplex (Seoane et al., 2002). We searched for such
a complex. argue that besides relieving Myc-mediated repression
from the proximal p21Cip1 promoter, TGF- inducesUsing chromatin immunoprecipitation (ChIP) assays,
we verified that TGF- action removes c-Myc from the the formation of a Smad complex that transactivates
p21Cip1 from the SBR (summarized in Figure 1A).p21Cip1 proximal promoter (Figure 1B). Simultaneously,
TGF- stimulated the binding of Smad2/3 and Smad4
to a more distal portion of this promoter (Figure 1B). Note A Critical Forkhead Site in the p21Cip1 Promoter
We noticed that the SBR also contains a consensusthat immunoprecipitating antibodies do not distinguish
between Smad2 and Smad3. Within this distal portion, Forkhead binding element (FHBE) immediately upstream
A Smad-Forkhead Signaling Node
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Figure 2. FoxO Proteins Bind and Transactivate the p21SBR
(A) FoxO family members. The DNA binding and transactivating domains are indicated.
(B and C) HaCaT cells were cotransfected with the indicated reporter constructs and Fox family members, treated with or without TGF- for
20 hr, and analyzed for luciferase activity.
(D) HaCaT cells were treated with or without TGF- for 1 hr, and ChIP assays were performed with the indicated antibodies and PCR primers.
(E) HaCaT cells were treated with or without TGF- for 1 hr, and lysates were subjected to mobility shift analysis with 32P end-labeled probes
corresponding to the wild-type SBR or the indicated mutant p21Cip1 SBR. Antibodies against Smad4 or Smad2/3 were added as indicated.
of the first SBE that is conserved in the human and and further increased by Smad overexpression (Figure
2C). It was not observed with other TGF- responsivemouse p21Cip1 promoters (Figure 1A). This element
closely matches the consensus binding site of the FoxO promoters (see Supplemental Figure S1A at http://www.
cell.com/cgi/content/full/117/2/211/DC1) and was notsubfamily of Forkhead factors (Furuyama et al., 2000)
(Figure 1A). This subfamily includes FoxO1, FoxO3, and mimicked by other Fox family members, including FoxA1
(formerly HNF3), FoxA2 (HNF3), or FoxH1 (FAST1)FoxO4 (formerly FKHR, FKHRL1, and AFX, respectively)
(Kaestner et al., 2000) (Figure 2A), all of which are present (Figure 2B). Thus, FoxO proteins function as specific
Smad partners in p21Cip1 activation.in HaCaT cells (see Figure 3A). FoxO factors can activate
the growth inhibitory and proapoptotic genes p27Kip1, TGF-addition rapidly induced the binding of endoge-
nous FoxO3, along with Smads 3 and 4, to the distalIGFBP1, Bim, Bcl-6, and FasL (Brunet et al., 1999; Cichy
et al., 1998; Dijkers et al., 2000; Medema et al., 2000; region of p21Cip1 promoter in vivo as detected by ChIP
(Figure 2D). Binding of FoxO1 and FoxO4 could not beTang et al., 2002). These genes, however, are not acti-
vated by TGF- in HaCaT or other epithelial cell lines investigated by ChIP because of a lack of suitable anti-
bodies. However, all three FoxO proteins specificallyanalyzed by DNA microarray (Kang et al., 2003).
We sought evidence that FoxO proteins participate in bound to a p21Cip1 SBR probe in vitro (see Supplemen-
tal Figure S1B at http://www.cell.com/cgi/content/full/p21Cip1 activation. Indeed, mutation of the p21Cip1
FHBE abrogated the TGF- response of this promoter 117/2/211/DC1). In vitro assays were also used to verify
that the SBE elements are involved in Smad binding.(Figure 1D), whereas overexpression of FoxO1, FoxO3,
or FoxO4 enhanced this response (Figure 2B). A FoxO TGF--dependent binding of Smad to this probe was
eliminated by mutations of the first and second SBEsmutant lacking  helix 3 (FoxO4H3), which is the DNA
binding element of FoxO proteins, or a construct (Fox- (probe mSBE1,2) or deletion of the third and fourth SBEs
(probe SBE3,4) but not by FHBE mutations (Figure 2E).O4H125R) with a point mutation in  helix 3 that disrupts
DNA binding (Clark et al., 1993) was inactive in this assay Smad binding was inhibited by excess unlabeled wild-
type probe or FHBE mutant probe but not SBE mutant(Figure 2B). FoxO-mediated induction of the p21Cip1
SBR in TGF--treated cells was dependent on the FHBE probe (see Supplemental Figure S1C). This set of results
Cell
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Figure 3. Smad-FoxO Interaction and Involvement in p21Cip1 Induction
(A and B) HaCaT cells were treated with or without TGF- for 1 hr, immunoprecipitated, and these precipitates subjected to immunobloting
with the indicated antibodies.
(C) COS-1 cells were transfected with vectors encoding HA-tagged FoxO proteins and Flag-tagged Smad proteins and treated with TGF-
for 1 hr. Cell lysates and anti-Flag immunoprecipitates were analyzed by immunoblotting with the indicated antibodies.
(D) Summary of interacting domains in FoxO3-Smad3 and FoxO3-Smad4 complexes. Lines connect the interacting domains.
(E) HaCaT cells infected with adenovirus vectors encoding dnFoxO1 or green fluorescent protein (GFP) were treated with TGF- or no additions,
immunoprecipitated with anti-Smad2/3 antibodies, and the immunocomplexes analyzed with anti-FoxO3 antibodies. Whole-cell extracts were
probed with the indicated antibodies. Other aliquots were used for anti-p21Cip1 immunoblotting or Northern blotting with the indicated probes.
(F) U87MG were transfected with pSUPERFoxO3 or pSUPERscrambled. After 30 hr, cells were serum starved for 16 hr and then incubated
with 20 M LY294002 for 2 hr and TGF- for 3 hr. Samples were subjected to Northern blot assays.
suggests that in response to TGF-, endogenous FoxO at http://www.cell.com/cgi/content/full/117/2/211/DC1).
For contrast, we reproduced the ability of Smads 2 andand Smad proteins rapidly and specifically bind to con-
tiguous sites on the p21Cip1 promoter and mediate 3 to bind FoxH1 via the MH2 domain (see Supplemental
Figure S2A) (Chen et al., 1997; Liu et al., 1997). Thep21Cip1 activation.
Smad-interacting region was mapped to the FoxO3 do-
main that includes the DNA binding site (see Supple-A FoxO-Smad Complex
The cooperation of Smad and Fox proteins in p21Cip1 mental Figures S2B and S2C). These interactions were
direct, as determined using purified GST fusion proteinsactivation suggested that these proteins may form a
TGF--regulated complex. Indeed, coimmunoprecipita- (see Supplemental Figure S2D). In sum, FoxO proteins
directly contact Smads 3 and 4, and this involves thetion experiments in HaCaT cells showed that endoge-
nous FoxO1, FoxO3, and FoxO4 bind to endogenous domains of FoxO and Smad that contain the DNA bind-
ing site (Figure 3D).Smad2/3 and Smad4 (Figures 3A and 3B). Formation of
these complexes was absolutely dependent on TGF-
stimulation, as was the formation of a Smad2/3-Smad4 FoxO Requirement for p21Cip1 Induction
We used two different approaches to test the require-complex (Lagna et al., 1996) used here as an internal
control (Figure 3A). When the Smad binding ability ment for FoxO in p21Cip1 activation by TGF-. In the
first, we used the FoxO1 deletion mutant dnFoxO1 (Na-of individual FoxO proteins was examined in TGF-
-treated cells, FoxO1, FoxO3, and FoxO4 bound to kae et al., 2001) that includes the Smad and DNA binding
domain but lacks a transactivation domain (Figure 3E).Smad3 and Smad4 but not to Smad1 (a mediator of
BMP signals, a separate branch of the TGF- family) or This mutant should compete with endogenous FoxO by
taking its place in contacting both Smads and the SBRSmad2 (Figure 3C). Smad2 is very similar in sequence
to Smad3, except that it contains an insert in the MH1 but without enabling transactivation. Indeed, expression
of dnFoxO via an adenovirus vector in HaCaT cellsdomain that blocks DNA binding (Shi et al., 1998). The
Smad2 splice variant that lacks this insert (Yagi et al., inhibited the formation of an endogenous FoxO-Smad
complex (Figure 3E, top) and completely eliminated1999) did bind FoxO proteins (data not shown).
The FoxO binding region was mapped to the MH1 the induction of p21Cip1 by TGF- (Figure 3E, bottom).
dnFoxO did not alter the activation of two other TGF-/domain of Smads 3 and 4 (see Supplemental Figure S2A
A Smad-Forkhead Signaling Node
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Smad target genes, Smad7 and plasminogen activator same experiments, LY294002 did not augment the PAI-1
response, indicating that its effect on p21Cip1 is selec-inhibitor-1 (PAI-1) (Figure 3E, bottom). The selectivity of
this effect argued that dnFoxO1 did not sequester tive (Figure 4B). LY294002 potentiated the p21Cip1 re-
sponse in other human cell types, including primary ker-Smads in general but rather targeted the p21Cip1 re-
sponse by interfering with the Smad-FoxO-SBR interac- atinocytes, a prostate carcinoma cell line expressing
PTEN, and Pten-defective prostate carcinoma, breasttion. Furthermore, dnFoxO1 did not prevent the down-
regulation of c-myc by TGF- (Figure 3E, bottom), carcinoma, and glioblastoma cell lines (Figure 4C).
A FoxO1 construct carrying mutations in the Akt phos-providing evidence that the drop in c-myc is not suffi-
cient for p21Cip1 induction when the FoxO-Smad com- phorylation sites and thus resistant to inhibition by
the PI3K/Akt pathway (Nakae et al., 2001) rescued theplex is disabled.
In the second approach, we knocked down the ex- p21Cip1 response to TGF- and the cytostatic response
in the Pten-defective glioblastoma cell line U87MG (Fig-pression of endogenous FoxO using RNAi. Three FoxO
proteins (FoxO 1, 3, and 4) redundantly mediate p21Cip1 ure 4D). This suggests that FoxO proteins are also tar-
gets of inhibition by the PI3K/Akt pathway when actingactivation in HaCaT cells, and our attempts at a triple
FoxO knockdown in this cell line were ineffective. How- as mediators of TGF- action.
ever, the U87MG human glioblastoma cell line expresses
FoxO3 predominantly. TGF- activates p21Cip1 expres- FoxG1 Is a FoxO Antagonist that Suppresses
sion in these cells in the presence of a PI3K inhibitor p21Cip1 Induction
(Figure 3F, and see below). When foxo3 expression was In light of the role of FoxO factors as Smad partners in
targeted in these cells using a short hairpin RNA, the p21Cip1 induction, we investigated whether FoxO would
induction of p21Cip1 by TGF-was specifically lost (Fig- be the long-sought target of the Forkhead family mem-
ure 3F). In the same cells and conditions, engaging the ber FoxG1 (formerly Brain Factor-1, BF1). FoxG1 is a
RNAi machinery in general by targeting a different tran- transcriptional repressor that protects neuroepithelial
script did not result in a blockade of p21Cip1 expression progenitor cells from cytostatic and differentiative sig-
(refer to Figure 6D). These results suggest that endoge- nals (Hanashima et al., 2002, 2004; Xuan et al., 1995).
nous FoxO is required for p21Cip1 induction by TGF-. FoxG1 expression is restricted to the neuroepithelial
progenitor population that comprises the telencephalon
in the developing mouse (Tao and Lai, 1992), and it isIntegration of Smad and PI3K Pathways
in p21Cip1 Control essential for forebrain formation (Hanashima et al., 2002,
2004; Xuan et al., 1995). Between embryonic day 11FoxO proteins are negatively regulated by the PI3K/
Akt pathway, which is activated by growth and survival (E11) and E18, an increasing fraction of neuroepithelial
progenitor cells in the dorsal telencephalon stop divid-cytokines such as insulin-like growth factor-1 (IGF-1)
and platelet-derived growth factor (PDGF) (Vivanco and ing and undergo differentiation (Takahashi et al., 1993,
1996). Embryos lacking foxg1 suffer hypoplasia of theSawyers, 2002). The product of PI3K, phosphatidylinosi-
tol (3,4,5) trisphosphate (PIP3), activates Akt, which then cerebral hemispheres, owing to a premature decay in
telencephalic progenitor cell proliferation (Xuan et al.,phosphorylates FoxO proteins, forcing them out of the
nucleus (Brunet et al., 1999). The PI3K/Akt pathway is 1995). foxg1/ mouse neuroepithelial cells are hyper-
sensitive to the cytostatic action of TGF- (Dou et al.,overactive in a wide range of tumors, owing to hyperacti-
vation of PI3K or Akt or inactivation of the PIP3 phospha- 2000). FoxG1 was shown to bind FoxH1 and Smads
when these proteins were overexpressed in lung epithe-tase tumor suppressor PTEN (Vivanco and Sawyers,
2002). As Smad partners in p21Cip1 activation and cell lial cell lines (Dou et al., 2000; Rodriguez et al., 2001).
Physiologically, however, FoxH1 is an unlikely target ofcycle control, FoxO proteins might therefore provide a
node for the antagonistic convergence of the PI3K/Akt FoxG1, because these proteins are not expressed in the
same cells. The mechanism of FoxG1 action and theand TGF-/Smad pathways.
We tested the effects of IGF-1 and the PI3K-specific relevance of its anti-TGF- effects therefore have re-
mained unknown.inhibitor LY294002 (Vlahos et al., 1994) on the p21Cip1
response to TGF- in HaCaT cells. As seen by indirect To determine whether FoxG1 may function as a physi-
ological suppressor of p21Cip1 expression, we con-immunofluorescence, endogenous FoxO3 protein was
distributed throughout the cytoplasm and nucleus and ducted anti-p21Cip1 immunohistochemistry assays on
the dorsal telencephalic neuroepithelium of wild-typebecame concentrated in the nucleus upon cell treatment
with LY294002 (Figure 4A) (Brunet et al., 1999). TGF- and foxg1 null mouse embryos at E12.5. The results
revealed that the mantle zone of the medial and dorsalhad no discernable effect on the subcellular distribution
of FoxO3 (Figure 4A). Western immunoblotting using telencephalic neuroepithelium in foxg1/ embryos con-
tains a high level of p21Cip1 compared to that of foxg1/antiphospho-Akt antibodies revealed a minimal increase
in the level of phosphorylated (activated) Akt in response littermates (Figure 5A).
Next, we investigated whether the high expression ofto IGF-1 (these cells were already stimulated by serum
factors), whereas LY294002 caused a marked decrease p21Cip1 in foxg1 null telencephalon could be due to
TGF- action. TGF-1 is expressed by the meningesin phospho-Akt, and TGF- had no effect (Figure 4B
and data not shown). LY294002 strongly increased the overlying the dorsal telencephalon as well as by scat-
tered cells in the ventricular zone and cortical platesensitivity of these cells to the cytostatic action of TGF-
(data not shown), as reported (Liang et al., 2002). (Miller, 2003). TGF-2 and TGF-3 are expressed by
radial glia (Flanders et al., 1991; Miller, 2003), cells thatLY294002 potentiated the induction of p21Cip1 by
submaximal concentrations of TGF- (Figure 4B). In the appear to be the primary neuronal progenitors in the
Cell
216
Figure 4. Integration of Smad and PI3K Pathways
(A) HaCaT cells were treated with 20 M LY294002 or treated with DMSO for 2 hr and then treated with TGF- for 1 hr. Endogenous FoxO3
was detected by immunofluorescence.
(B) HaCaT cells were incubated for 2 hr with LY294002 or 100 ng/ml IGF-1 or left untreated, then treated with the indicated concentrations
of TGF- for 3 hr prior to Northern blotting assays or for 5 hr prior to immunoblotting assays.
(C) Primary keratinocytes and the indicated cell lines were incubated with or without LY294002 for 2 hr and then with or without 10 pM TGF-
for 3 hr and were subjected to Northern blotting.
(D) U87MG cells infected with adenovirus vectors encoding FoxO1ADA or GFP were incubated with LY294002 and then with or without TGF-
for 3 hr. Samples were subjected to Northern blotting. 125I-BrdU incorporation assays were performed on parallel cultures. “% growth inhibition”
refers to the percent drop in 125I-BrdU incorporation compared to controls.
dorsal telencephalon (Tamamaki et al., 2001; Noctor et expression selectively blocked the induction of p21Cip1
by TGF- (Figure 5C), and it also blocked transactivational., 2002; Malatesta et al., 2003). Furthermore, activated
(receptor phosphorylated) Smad2 is present in the dor- from the p21Cip1 SBR by TGF- and FoxO proteins
(Figure 5D). Another Fox family member with transcrip-sal telencephalon (de Sousa Lopes et al., 2003), a point
that we confirmed by antiphospho-Smad2 immunohis- tional repressor activities, FoxN3 (Scott and Plon, 2003),
did not affect the SBR response to TGF- (data nottochemistry (data not shown). Thus, the developing tel-
encephalon is exposed to Smad-activating TGF- sig- shown).
Evidence that FoxG1 can directly target FoxO proteinsnals. To determine if such signals can increase p21Cip1
levels when FoxG1 is absent, neuroepithelial progenitor was provided by the ability to coimmunoprecipitate
these proteins from transfected cells (Figure 5E) or en-cells were isolated from the telencephalon of E10.5 mice
and treated with TGF- (Figure 5B). At E10.5, there is dogenously (see Figure 6C). These interactions were
independent of TGF- addition. Using FoxO3 and FoxG1no major difference yet in brain development between
the wild-type and foxg1 null mice (Xuan et al., 1995). deletion constructs, the interacting domains were mapped
to the N-terminal half of FoxO3 and the C-terminal regionTGF- induced the expression of p21Cip1 and inhibited
cell proliferation in foxg1 null neuroepithelial cells but of FoxG1 (Figure 5F and see Supplemental Figure S3 at
http://www.cell.com/cgi/content/full/117/2/211/DC1).not in their wild-type or heterozygote counterparts (Fig-
ure 5B). Thus, loss of FoxG1 enables the induction of FoxG1 did not compete with Smad3 or Smad4 for bind-
ing to FoxO3 (Figure 5G) but rather formed a complexp21Cip1 and growth inhibition by TGF-.
To determine how FoxG1 interferes with p21Cip1 by with these three proteins, as determined by sequential
coimmunoprecipitation (see Supplemental Figure S3E).TGF-, we overexpressed FoxG1 in HaCaT keratino-
cytes and DU145 prostate carcinoma cells. FoxG1 over- These results suggest that FoxG1 is a direct inhibitor of
A Smad-Forkhead Signaling Node
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Figure 5. FoxG1 as a FoxO Antagonist
(A) p21Cip1 immunohistochemistry performed on horizontal paraffin sections of telencephalon from foxg1/ and foxg1/ mouse embryos at
E12.5. p21Cip1 is present in the nuclei of the mantle zone in the dorsal telencephalon of foxg1/ mice.
(B) Telencephalic neuroepithelial cells isolated from foxg1/, foxg1/, or foxg1/ littermates were plated in the presence or absence of
TGF- for 5 hr, lysed, and subjected to p21Cip1 and FoxG1 immunoblot assays. 125I-BrdU incorporation was determined in parallel cultures
incubated with TGF- for 20 hr.
(C) DU145 cells and HaCaT cells expressing exogenous FoxG1 or GFP as a control were incubated with 10 pM TGF- for 3 hr prior to Northern
blotting assays or for 5 hr prior to immunoblotting assays.
(D) HaCaT cells were cotransfected with the p21Cip1 SBR reporter construct and vectors encoding FoxO family members and FoxG1 as
indicated. Cells were treated with or without 100 pM TGF- for 20 hr and luciferase activity was determined.
(E) COS-1 cells were transfected with vectors encoding HA-tagged FoxO proteins and Myc-tagged FoxG1. Anti-HA immunoprecipitates and
whole-cell lysates were subjected to immunoblotting with the indicated anti-tag antibodies.
(F) Summary of FoxG1-FoxO3 interaction domains. N and C termini are indicated.
(G) COS-1 cells expressing Flag-FoxO3 and increasing amounts of Myc-FoxG1 were treated with TGF- for 1 hr prior to anti-Flag immunoprecipi-
tation and immunoblotting of the precipitates or of whole-cell lysates with the indicated antibodies.
the FoxO-Smad transcriptional complex and a blocker Rich et al., 1999) and a gain of TGF--mediated PDGF
production and cell proliferation (Jennings et al., 1997).of p21Cip1 induction by TGF- signals in neuroepithe-
lial cells. Analysis of several human grade II glioma (oligoden-
drocytoma, astrocytoma) and glioblastoma multiforme
tumor samples (Figure 6A) and glioblastoma cell linesFoxG1 and PI3K Mediate Glioblastoma Resistance
to TGF- Cytostasis (Figure 6B) confirmed our suspicion that many of these
tumors express FoxG1. U87MG glioblastoma cells re-Given the ability of the PI3K/Akt pathway and the
FoxG1 pathway to inhibit p21Cip1 induction by a TGF- spond to TGF- with PAI-1 induction but not p21Cip1
induction (refer to Figure 4D) and are resistant to growth-activated Smad-FoxO complex, we asked whether
these activities underlie the resistance of brain tumor inhibition (Figure 6F). Using U87MG cells as a model
system, we verified that the endogenous FoxG1 andcells to the cytostatic action of TGF-. Brain tumor pro-
gression to the most aggressive stage, glioblastoma FoxO3 proteins are in a complex (Figure 6C). Addition-
ally, U87MG cells have a hyperactive PI3K pathway,multiforme, occurs with a loss of TGF--mediated p21Cip1
induction and cytostasis (Jennings and Pietenpol, 1998; owing to the loss of Pten function (Li et al., 1997), which
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Figure 6. Role of FoxG1 and PI3K in Glioblas-
toma Resistance to TGF- Cytostasis
(A and B) Samples of human glioblastoma
multiforme (GBM) and grade II glioma tumors
(O, oligodendrocytoma; O/A, mixed oligoden-
drocytoma/astrocytoma) and human glioblas-
toma cell lines, COS-1 cells overexpressing
FoxG1 (a positive control), and HaCaT cells
(a negative control) were subjected to anti-
FoxG1 immunoblotting. (C) Anti-FoxO3 and
control (IgG) immunoprecipitates from U87MG
cells were subjected to anti-FoxG1 immuno-
blotting. (D) Subconfluent or (E) confluent
U87MG cell cultures were transfected with
foxg1 siRNA or with a control siRNA. After
48 hr, cells were serum starved for 16 hr and
incubated with LY294002 or DMSO for 2 hr
and then with TGF- for 3 hr or the indicated
times. Samples were subjected to Northern
blot or protein immunoblot assays. (F) Sub-
confluent U87MG cells transfected with foxg1
siRNA or mock transfected were incubated
for 20 hr with 2 M LY294002 and either anti-
TGF- antibody or the indicated concentra-
tions of TGF-. 125I-BrdU incorporation was
determined.
is characteristic of many glioblastomas (Holland, 2001; (Siegel and Massague´, 2003). Previous work showed
that a c-Myc-Miz complex prevents p21Cip1 activationZhu and Parada, 2002). TGF- induced p21Cip1 expres-
sion and growth inhibition when U87MG cells were (Herold et al., 2002; Seoane et al., 2002; van de Wetering
et al., 2002; Wu et al., 2003), and TGF- relieves thistreated with PI3K inhibitor (Figures 4C and 6D). To inves-
tigate the involvement of FoxG1, we treated these cells impediment by downregulating c-myc (Claassen and
Hann, 2000; Seoane et al., 2002). We have now identifiedwith foxg1 siRNA. Individually, and more so when com-
bined, foxg1 siRNA and LY294002 rescued a strong a TGF--induced Smad-FoxO complex that specifically
targets p21Cip1 to deliver the activating input. The find-p21Cip1 response to TGF- (Figure 6D). The strength
of this response varied depending on culture conditions, ing that FoxO proteins fulfill this role carries unexpected
implications for the control of cell proliferation and can-being strongest in confluent cell monolayers (Figure 6E).
This p21Cip1 induction was accompanied by a rescue cer, especially in epithelia and the brain.
of TGF- growth inhibitory effect (Figure 6F). Addition
of anti-TGF- blocking antibodies to the media showed FoxO Factors as Signal Transducers
Our evidence shows that FoxO proteins are physicallythat autocrine TGF-may stimulate U87MG cell prolifer-
ation under basal conditions but suppresses prolifera- and functionally engaged as mediators of p21Cip1 acti-
vation by TGF- (Figure 7). In response to TGF-, Smad3tion in the presence of foxg1 siRNA and PI3K inhibitors
(Figure 6F). Collectively, these results suggest that FoxG1 and Smad4 bind to FoxO1, FoxO3, or FoxO4 and target
a region of the p21Cip1 promoter that contains contigu-and a hyperactive PI3K pathway cooperate to block
p21Cip1 induction and cytostasis by the TGF- pathway ous FHBE and SBE sites. These sites are required for
FoxO and Smad binding and TGF--induced transacti-in these human glioblastoma cells.
vation of p21Cip1. When endogenous FoxO is disabled
by RNAi-mediated knockdown or by a dominant-nega-Discussion
tive FoxO construct, p21Cip1 induction is lost, while
other TGF- gene responses remain. Ongoing workTranscriptional induction of p21Cip1 is central to the
TGF- cytostatic program and is under tight control shows that the latter treatment inhibits approximately
A Smad-Forkhead Signaling Node
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Figure 7. Model of FoxO Factors as a Node
for Integration of TGF-/Smad, PI3K/Akt, and
FoxG1 Pathways
TGF- receptor activation leads to Smad3
phosphorylation (P) and assembly of a Smad3-
Smad4 complex in the nucleus. This complex
associates with FoxO proteins to target the
p21Cip1 promoter for activation. IGF-1-like
proliferative signals activate the PI3K/Akt
pathway, which phosphorylates FoxO, lead-
ing to their exclusion from the nucleus (Brunet
et al., 1999) and preventing Smad-FoxO-
dependent gene activation. Expressed as
part of a neural progenitor proliferation pro-
gram, FoxG1 binds to the FoxO-Smad com-
plex, inhibiting its transcriptional activity. Thus,
three countervailing pathways converge on
FoxO to tightly regulate the expression of
p21Cip1 and cell proliferation.
15 out of a total of 118 TGF- early gene activation (Figure 7). The involvement of FoxO factors in the TGF-
responses in HaCaT cells. Thus, the results suggest that pathway is inhibited by the PI3K/Akt and FoxG1 path-
FoxO mediates a small subset of TGF- gene responses, ways, each acting by a distinct mechanism. Akt is known
including p21Cip1 activation. to phosphorylate FoxO proteins and induce their exclu-
TGF- stimulates the binding of FoxO and Smad pro- sion from the nucleus (Brunet et al., 1999). We provide
teins to the p21Cip1 promoter while relieving it from evidence that FoxO proteins are also targets of inhibition
c-Myc-mediated inhibition. The FoxO-Smad binding by the PI3K/Akt pathway when acting as mediators of
region defined here, the SBR, is separate from the TGF- action. FoxG1, on the other hand, binds to the
c-Myc-Miz binding region. c-Myc does not interfere with FoxO-Smad complex, blocking its ability to activate
Smad binding or transactivation when the SBR is iso- p21Cip1. FoxG1 can recruit corepressors (Tan et al.,
lated from the natural promoter. c-Myc downregulation 2003; Yao et al., 2001), so its presence may turn a FoxO-
alone does not suffice for p21Cip1 activation, arguing Smad into a repressor complex.
that the FoxO-Smad complex mediates p21Cip1 trans- Inhibition of the p21Cip1 transcriptional response to
activation once repression by c-Myc is removed. In this TGF- is one of several actions by which the PI3K/
regard, the FoxO-Smad complex acts similarly to p53 Akt pathway protects the activity of cyclin-dependent
activated by DNA damage (Seoane et al., 2002). kinases. Akt may also phosphorylate p21Cip1 and
FoxO proteins might act as signal transducers in other p27Kip1 and force these Cdk inhibitors out of the nu-
pathways as well. Although FoxO proteins can bind to cleus (Li et al., 2002; Liang et al., 2002; Shin et al., 2002;
the FHBE in vitro without other participating factors Viglietto et al., 2002; Zhou et al., 2001). The Ras/MAPK
(Brunet et al., 1999), their binding to the p21Cip1 FHBE pathway downstream of receptor tyrosine kinases also
in vivo is dependent on TGF- stimulation and involves interferes with TGF- signaling, but in this case, Smads
Smad proteins. The same or a very similar FHBE is pres- are the direct targets (Massague´, 2003). Akt-mediated
ent in many actual or predicted FoxO target genes (Furu- phosphorylation of FoxO proteins provides a more se-
yama et al., 2000; Samatar et al., 2002). FoxO binding lective node for the integration of mitogenic signals and
to other target promoters may also require the participa- TGF- cytostatic signals. Based on genetic evidence, it
tion of signal-regulated factors, much like FoxO binding
was proposed that TGF- signaling in Caenorhabditis
to the p21Cip1 promoter requires TGF--activated
elegans affects the PI3K pathway upstream of the FoxO
Smads.
ortholog and longevity regulator daf-16 (Lee et al., 2001).Another Forkhead family member, FoxH1, serves as
In human keratinocytes and glioblastoma cells studieda Smad partner in the activation of Mix.2 (Chen et al.,
here, however, TGF- does not alter the level of phos-1996), goosecoid (Labbe´ et al., 1998), and other genes
pho-Akt or the subcellular localization of FoxO.(Watanabe and Whitman, 1999; Hoodless et al., 2001)
during mesoderm formation in vertebrates. However,
Evasion of Cytostasis in NeuroepithelialFoxH1 and FoxO act differently as Smad partners.
Development and Glioblastoma ProgressionFoxH1 is a partner of Smad2 (Chen et al., 1996), and
We provide evidence for the involvement of the Smad/the binding is via their C-terminal domains (Chen et al.,
PI3K/FoxG1 node in the evasion of TGF- cytostatic1997; Liu et al., 1997). In contrast, FoxO proteins act as
effects in telencephalic neuroepithelial progenitors andpartners of Smad3 (and Smad4) via the FoxO and Smad
in glioblastoma cells. FoxG1 is essential for forebrainN-terminal domains.
formation, because it protects neuroepithelial progeni-
tor cells from premature growth arrest and differentia-FoxO as a Node for Integration of Three Pathways
tion (Hanashima et al., 2004, 2002; Xuan et al., 1995).FoxO factors are shown to act as a nodal point for the
integration of the Smad, PI3K, and FoxG1 pathways TGF- expression (Flanders et al., 1991; Miller, 2003)
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coated dishes with DMEM-F12 media containing 1% FBS and 20 ng/mland Smad activation (de Sousa Lopes et al., 2003) are
fibroblast growth factor 2. TGF- (100 pM) was added as indicated.present in the dorsal telencephalon at E12.5. At this
stage, foxg1 null mice suffer a sharp decline in telence-
Transfections and Infectionsphalic growth (Xuan et al., 1995). We show here that the
DU145 cells were transfected with pCMV-GFP and Flag-FoxG1underdeveloped telencephalic neuroepithelium of these
as indicated. HaCaT cells were transfected with pIRES2-EGFP
mice contains a high level of p21Cip1, compared to or pFoxG1-IRES-GFP, and GFP positive cells were sorted on a
the neuroepithelium of wild-type littermates. Moreover, Vantage cell sorter before analysis. Cos-1 and DU-145 cell transfec-
neuroepithelial progenitor cells from foxg1 null mice but tions were performed using Lipofectamine (Invitrogen). Adenovirus
Ad-dnFoxO1(FoxO1256), Ad-FoxO1ADA, and Ad-GFP were ampli-not their heterozygous counterparts respond to TGF-
fied and tritrated. Cells were grown to 70% confluence and infectedwith p21Cip1 induction and growth arrest. We suggest
with recombinant adenovirus at a MOI of 20 for 3 hr. Twenty-fourthat during the development of the telencephalon,
hours after the infection, cells were treated as described.
FoxG1 prevents endogenous TGF- signals from trig-
gering p21Cip1 expression and cytostasis in the neuro-
Immunoprecipitation and Oligonucleotide
epithelium. Precipitation Assays
Selective pressure against TGF- cytostatic responses Assays were performed as previously described (Seoane et al., 2001)
is strong during tumor progression (Derynck et al., 2001; in binding buffer (20 mM HEPES [pH 7.9], 50 mM KCl, 2 mM MgCl2,
0.5 mM EDTA, 10% glycerol, 2 mM DTT, 10 mM NaF, 20 mMDumont and Arteaga, 2003; Massague´ et al., 2000;
-glycerophosphate, 0.05% NP-40, and protease inhibitor cocktail).Wakefield and Roberts, 2002). Mutational inactivation
of TGF- receptors or Smad4 occurs in a significant
Electrophoretic Mobility Shift Assayproportion of pancreatic and gastrointestinal cancers,
Whole-cell extracts from HaCaT or COS-1 cells were prepared bybut it is relatively rare in other cancers. More commonly,
lysing the cells in a Triton X-100-containing buffer (Page`s et al.,tumor cells selectively lose cytostatic responsiveness
1994). Complementary oligonucleotides corresponding to the p21SBR
while retaining a functional TGF- receptor and Smad and its mutants were annealed and end labeled with 32P-ATP. The
system. The molecular basis for this selective loss is binding reactions were performed and analyzed on a 5% nondena-
turing gel (Brunet et al., 1999). For supershift studies, 1l of antibodyunknown in most instances. With the cytostatic action
against Smad2/3, Smad4, FoxO1, FoxO3, or FoxO4 was preincu-disabled, TGF- may go on to stimulate proliferation,
bated for 5 min on ice with the cell extract. DNA-protein complexesinvasion, and metastasis of tumor cells. Glioblastomas
were visualized by autoradiography.go through such a transition by suffering a selective
loss of cytostatic responsiveness while still producing
Chromatin Immunoprecipitationautocrine PDGF in response to TGF- (Jennings et al.,
Cells were grown to 70% confluence, treated with TGF- for 60 min,
1997; Jennings and Pietenpol, 1998; Rich, 2003). Glio- and then crosslinked with 1% formaldehyde at room temperature
blastoma tumor formation is driven by a combination of for 10 min. ChIP assays were performed as previously described
hyperactive PI3K/Akt and Ras/MAPK pathways together (Shang et al., 2000).
with frequent inactivation of Pten and Ink4-Arf tumor
suppressor genes (Holland, 2001; Zhu and Parada, In Vitro Protein Binding Assay
Bacterially-expressed Smad domain and FoxO domain GST-fusion2002). Here, we have shown that a hyperactive PI3K/
proteins were purified by affinity chromatography using GlutathioneAkt pathway and high levels of FoxG1 in glioblastoma
Sepharose 4B (Amersham Pharmacia Biotechnology). Recombinantcells cooperate to prevent p21Cip1 induction and cyto-
His-tagged full-length FoxO3 was purified with Ni-NTA Agarose
stasis by the TGF-/Smad-FoxO pathway. By attenuat- Beads (Qiagen). GST-fusion protein (15 g) was incubated with ei-
ing PI3K and FoxG1 functions, we have been able to ther 15 g or 45 g of His-tagged FoxO3 in binding buffer (20 mM
restore TGF- cytostatic action to glioblastoma cells. HEPES [pH 7.9], 50 mM KCl, 2 mM MgCl2, 0.5 mM EDTA, 10%
glycerol, 2 mM DTT, 0.05% NP-40, 0.2 mg/ml BSA) for 3 hr at 4	C.These observations lend support to the idea of therapeu-
GST-fusion proteins were precipitated with glutathione sepharosetically targeting the PI3K pathway (Vivanco and Saw-
beads, and bound proteins were separated by SDS-PAGE and im-yers, 2002) and FoxG1 in glioblastoma, one of the most
munoblotted with anti-His antibody.
devastating human malignancies.
Immunohistochemistry and Immunofluorescence
Experimental Procedures E12.5 embryos were fixed and embedded in paraffin as described
(Xuan et al., 1995). Immunohistochemical detection was performed
Cell Lines with an automated Discovery Staining Module (Ventana Medical
Cell lines were maintained in DMEM supplemented with 10% fetal systems, Tucson, AZ) using an anti-p21 antibody (F-5, Santa Cruz
bovine serum. Primary keratinocytes were purchased from Cambrex Biotechnologies, 10 mg/ml) and hematoxilin counterstaining. Immu-
and maintained in the manufacturer’s medium. PC3 cells were main- nofluorescence analysis was carried out with anti-FoxO3 antibodies
tained in F12 supplemented with 10% FBS. BT549 cells were main- (Upstate Biotechnology) and FITC-conjugated goat anti-rabbit IgG
tained in RPMI supplemented with 10% FBS and insulin 0.02IU. The antibodies (Jackson Immunoresearch).
HaCaT-tetMyc cell line has been described (Seoane et al., 2002).
Small Interfering RNA
siRNA duplexes targeting foxg1 were purchased from DharmaconIsolation and Culture of Primary Neuroepithelial Cells
Telencephalic neuroepithelial cells were isolated from E10.5 C57BL6 Research. The coding strand of the siRNA was UCUGUCCCUCAA
CAAGUGCdTdT. U87MG cells were transfected with siRNA du-mouse as previously described (Dou et al., 2000). Embryos from
foxg1/ 
 foxg1/ heterozygote matings were dissected in ice- plexes using Oligofectamine (Invitrogen) and used 48 hr after trans-
fection. FoxO3 was targeted with pSUPERFoxO3 kindly providedcold Hank’s balanced salt solution. The epidermis of the head was
removed, and the neuroepithelium of the telencephalon was dis- by A. Brunet (Harvard Medical School). pSUPERFoxO3 or pSUPER-
scrambled that contains an unrelated sequence was transfectedsected. The isolated neuroepithelium was dissociated into a cell
suspension by repeated pipetting in DMEM supplemented with 10% into U87MG cells using Lipofectamine2000. Forty hours after trans-
fection, cells were lysed and processed for Northern blotting.fetal bovine serum. Cells were plated on poly-L-lysine and laminin-
A Smad-Forkhead Signaling Node
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